Related Experiment Video

Updated: Jun 30, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.1K

Recommendations for hypolipidemic and antithrombotic therapy in HCV-infected patients treated with direct-acting

Jerzy Jaroszewicz1, Marlena Broncel2, Anna Piekarska3

  • 1Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, Poland.

Clinical and Experimental Hepatology
|April 23, 2026
PubMed

Insights

Hepatitis C virus (HCV) infection is a new cardiovascular disease risk factor, potentially causing metabolic disorders. Expert recommendations guide heart disease and lipid disorder diagnosis and treatment in HCV patients.

Area of Science:

  • Hepatology
  • Cardiology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection is increasingly linked to cardiovascular disease (CVD) incidence.
  • HCV contributes to metabolic disorders like obesity, insulin resistance, diabetes, and fatty liver, termed metabolic-viral syndrome.
  • These metabolic disorders are significant contributors to CVD development.

Purpose of the Study:

  • To provide expert recommendations for diagnosing and treating heart disease in patients with HCV infection.
  • To offer guidance on managing lipid disorders in the context of HCV infection.
  • To address the growing concern of HCV as a non-classical cardiovascular risk factor.

Main Methods:

  • Review of current literature on HCV, cardiovascular disease, and metabolic disorders.
  • Synthesis of expert opinions and clinical experience.
  • Development of evidence-based recommendations for clinical practice.

Main Results:

  • HCV is recognized as a non-classical risk factor for cardiovascular diseases.
  • Metabolic disorders associated with HCV infection significantly impact cardiovascular health.
  • Direct-acting antiviral drugs offer effective HCV treatment, with drug interactions being a key consideration.

Conclusions:

  • Management of cardiovascular and lipid disorders is crucial in HCV-infected patients.
  • Expert recommendations aim to improve patient outcomes by addressing these comorbidities.
  • Integrated care approaches are necessary for patients with HCV and associated metabolic and cardiovascular issues.

Keywords:
HCV infectionanticoagulantscardiovascular diseasesdirect-acting antiviralslipid-lowering drugs

More Related Videos

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

9.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...